Fludarabine
Recurrent Childhood Medulloblastoma
City of Hope Medical CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Recurrent Childhood Medulloblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
FILGRASTIM Mayo Clinic | Phase 3 | BB |
Hycamtin City of Hope Medical Center | Phase 2 | BB |
Irinotecan National Cancer Institute (NCI) | Phase 2 | BB |
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- National Cancer Institute (NCI) | Phase 2 | B |
View all 33 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →